SAN DIEGO--Aurora Biosciences announced a two-year collaboration in which it will allow the US National Cancer Institute use of its proprietary GenomeScreen technology to locate rare or low abundance transcripts in tumor cells. These transcripts often cause problems for traditional gene capture methods, and are obstacles to completing the sequencing of the entire human genome.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.